Moreover, blockade to the PD1/PD-L1 axis has been approved by the FDA and shows groundbreaking progress in improving HNSCC patients’ survival time (Tsangaris et al., 1969). The gene discussed is CD274; the disease is head and neck squamous cell carcinoma.